

Tadashi Namisaki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3907980/publications.pdf>

Version: 2024-02-01

115
papers

2,529
citations

218381

26
h-index

233125

45
g-index

119
all docs

119
docs citations

119
times ranked

3489
citing authors

#	ARTICLE	IF	CITATIONS
1	The Effect of Inflammatory Cytokines in Alcoholic Liver Disease. <i>Mediators of Inflammation</i> , 2013, 2013, 1-10.	1.4	183
2	Plasma Endotoxin and Serum Cytokine Levels in Patients With Alcoholic Hepatitis: Relation to Severity of Liver Disturbance. <i>Alcoholism: Clinical and Experimental Research</i> , 2000, 24, 48S.	1.4	157
3	Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. <i>Hepatology</i> , 2006, 44, 983-991.	3.6	142
4	Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. <i>International Journal of Cancer</i> , 2018, 142, 1712-1722.	2.3	136
5	Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2017, 152, 1383-1394.	0.6	115
6	Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. <i>Journal of Gastroenterology</i> , 2014, 49, 481-491.	2.3	107
7	Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. <i>World Journal of Gastroenterology</i> , 2017, 23, 8355-8366.	1.4	85
8	Bezafibrate Improves GLOBE and UKâ€PBC Scores and Longâ€Term Outcomes in Patients With Primary Biliary Cholangitis. <i>Hepatology</i> , 2019, 70, 2035-2046.	3.6	83
9	Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. <i>Molecular Medicine Reports</i> , 2015, 11, 1693-1700.	1.1	62
10	Sulforaphane ameliorates ethanol plus carbon tetrachloride-induced liver fibrosis in mice through the Nrf2-mediated antioxidant response and acetaldehyde metabolism with inhibition of the LPS/TLR4 signaling pathway. <i>Journal of Nutritional Biochemistry</i> , 2021, 89, 108573.	1.9	58
11	Therapeutic strategies for alcoholic liver disease: Focusing on inflammation and fibrosis (Review). <i>International Journal of Molecular Medicine</i> , 2017, 40, 263-270.	1.8	49
12	Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. <i>BMC Research Notes</i> , 2009, 2, 70.	0.6	48
13	Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. <i>Hepatology Research</i> , 2020, 50, 840-852.	1.8	46
14	Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 300, G1094-G1104.	1.6	44
15	Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. <i>Biomedical Reports</i> , 2016, 4, 183-187.	0.9	42
16	Cross talk between tollâ€like receptorâ€4 signaling and angiotensinâ€II in liver fibrosis development in the rat model of nonâ€alcoholic steatohepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 723-730.	1.4	41
17	Ipragliflozin, a sodiumâ€glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Longâ€Evans Tokushima fatty rats. <i>Journal of Gastroenterology</i> , 2016, 51, 1141-1149.	2.3	39
18	Differential Expression of Drug Uptake and Efflux Transporters in Japanese Patients with Hepatocellular Carcinoma. <i>Drug Metabolism and Disposition</i> , 2014, 42, 2033-2040.	1.7	38

#	ARTICLE	IF	CITATIONS
19	Angiotensin-II induces the tissue inhibitor of metalloproteinases-1 through the protein kinase-C signaling pathway in rat liver fibrosis development. <i>Hepatology Research</i> , 2003, 27, 51-56.	1.8	35
20	Salvage effect of the vascular endothelial growth factor on chemically induced acute severe liver injury in rats. <i>Journal of Hepatology</i> , 2006, 44, 568-575.	1.8	33
21	Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients. <i>Antibiotics</i> , 2020, 9, 145.	1.5	33
22	Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein. <i>Cancer Letters</i> , 2018, 434, 120-129.	3.2	31
23	Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis. <i>Journal of Gastroenterology</i> , 2016, 51, 162-172.	2.3	30
24	Predictive parameter of tolvaptan effectiveness in cirrhotic ascites. <i>Hepatology Research</i> , 2017, 47, 854-861.	1.8	30
25	Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study. <i>Journal of Gastroenterology</i> , 2018, 53, 1151-1158.	2.3	29
26	von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C. <i>United European Gastroenterology Journal</i> , 2018, 6, 1401-1409.	1.6	27
27	Impact of insulin resistance on the progression of chronic liver diseases. <i>International Journal of Molecular Medicine</i> , 2008, 22, 801-8.	1.8	26
28	Direct renin inhibitor, aliskiren, attenuates the progression of nonalcoholic steatohepatitis in the rat model. <i>Hepatology Research</i> , 2013, 43, 1241-1250.	1.8	25
29	Combining probiotics and an angiotensin type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis. <i>Hepatology Research</i> , 2019, 49, 284-295.	1.8	25
30	Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis. <i>Hepatology Research</i> , 2017, 47, 1317-1328.	1.8	22
31	Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5589.	1.8	21
32	Dual blockade of angiotensin and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis. <i>Hepatology Research</i> , 2013, 43, 765-774.	1.8	20
33	VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2019, 19, 167.	0.8	20
34	Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model. <i>Oncotarget</i> , 2018, 9, 28638-28651.	0.8	18
35	Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient L-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2724.	1.8	18
36	Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis. <i>Microorganisms</i> , 2020, 8, 925.	1.6	18

#	ARTICLE	IF	CITATIONS
37	Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis. <i>Journal of Gastroenterology</i> , 2014, 49, 1421-1429.	2.3	17
38	Symptoms and health-related quality of life in Japanese patients with primary biliary cholangitis. <i>Scientific Reports</i> , 2018, 8, 12542.	1.6	17
39	Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization. <i>Oncology Letters</i> , 2017, 14, 3028-3034.	0.8	16
40	TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats. <i>Cells</i> , 2019, 8, 1153.	1.8	16
41	Efficacy of Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumor. <i>Clinical Endoscopy</i> , 2021, 54, 371-378.	0.6	16
42	Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6921.	1.8	16
43	Liver fibrosis progression predicts survival in patients with primary biliary cirrhosis. <i>Hepatology Research</i> , 2017, 47, E178-E186.	1.8	14
44	A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis. <i>Liver International</i> , 2020, 40, 1926-1933.	1.9	14
45	Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2017, 23, 6705-6714.	1.4	14
46	The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects. <i>Cells</i> , 2021, 10, 575.	1.8	13
47	Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 741-749.	0.6	12
48	Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2164.	1.8	12
49	Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 985-995.	0.8	12
50	Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis. <i>Hepatology Communications</i> , 2017, 1, 928-945.	2.0	11
51	Clinical significance of the Scheuer histological staging system for primary biliary cholangitis in Japanese patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 23-30.	0.8	11
52	Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1635.	1.0	11
53	Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4001-4013.	1.6	11
54	Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 381-389.	4.5	11

#	ARTICLE	IF	CITATIONS
55	Association between ADAMTS13 activity and VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2020, 26, 7232-7241.	1.4	11
56	Periostin cross-reacts with the renin-angiotensin system during liver fibrosis development. <i>Molecular Medicine Reports</i> , 2017, 16, 5752-5758.	1.1	10
57	Platelet hyperaggregability is associated with decreased ADAMTS13 activity and enhanced endotoxemia in patients with acute cholangitis. <i>Hepatology Research</i> , 2018, 48, E52-E60.	1.8	10
58	Glycogenic Hepatopathy in Type 1 Diabetes Mellitus. <i>Internal Medicine</i> , 2018, 57, 1087-1092.	0.3	10
59	Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7588.	1.8	10
60	The association between sarcopenia and endotoxin in patients with alcoholic cirrhosis. <i>Medicine (United States)</i> , 2021, 100, e27212.	0.4	10
61	Enhanced liver fibrosis score as a surrogate of liver-related complications and mortality in primary biliary cholangitis. <i>Medicine (United States)</i> , 2021, 100, e27403.	0.4	10
62	Novel oral plasminogen activator inhibitor-1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats. <i>Molecular Medicine Reports</i> , 2020, 22, 2948-2956.	1.1	10
63	Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity. <i>World Journal of Gastroenterology</i> , 2021, 27, 8323-8342.	1.4	10
64	Aortic Valve Replacement for the Management of Heyde Syndrome: A Case Report. <i>Journal of Nippon Medical School</i> , 2017, 84, 193-197.	0.3	9
65	Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis. <i>Hepatology Research</i> , 2019, 49, 1147-1161.	1.8	9
66	Identification of clinical risk factors for histological progression of primary biliary cholangitis. <i>Hepatology Research</i> , 2019, 49, 1015-1025.	1.8	9
67	Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis. <i>Hepatology Research</i> , 2019, 49, 232-238.	1.8	9
68	Chronic Alcohol Consumption is Inversely Associated with Insulin Resistance and Fatty Liver in Japanese Males. <i>Nutrients</i> , 2020, 12, 1036.	1.7	9
69	Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure. <i>Journal of Clinical Medicine</i> , 2020, 9, 1467.	1.0	8
70	ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 424-435.	0.8	8
71	Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control study. <i>Journal of Gastroenterology</i> , 2022, 57, 19-29.	2.3	8
72	ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability. <i>Journal of Clinical Medicine</i> , 2022, 11, 1835.	1.0	8

#	ARTICLE	IF	CITATIONS
73	A potent angiogenic factor, vascular endothelial growth factor, improves the survival of the on-going acute hepatic failure in rats. <i>Hepatology Research</i> , 2006, 35, 199-203.	1.8	7
74	The vascular endothelial growth factor (VEGF) receptor-2 is a major regulator of VEGF-mediated salvage effect in murine acute hepatic failure. <i>Journal of Angiogenesis Research</i> , 2010, 2, 16.	2.9	7
75	Accuracy of Fibrosis-4 Index in Identification of Patients with Cirrhosis Who Could Potentially Avoid Variceal Screening Endoscopy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3510.	1.0	7
76	Effect of L-carnitine on health-related quality of life in patients with liver cirrhosis. <i>Biomedical Reports</i> , 2020, 13, 1-1.	0.9	7
77	Machine learning in primary biliary cholangitis: A novel approach for risk stratification. <i>Liver International</i> , 2022, 42, 615-627.	1.9	7
78	Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute-on-chronic liver failure development and prognosis in patients with liver cirrhosis. <i>Hepatology Research</i> , 2022, 52, 390-400.	1.8	7
79	Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis. <i>Digestive and Liver Disease</i> , 2022, 54, 1392-1402.	0.4	7
80	Treatment of long-segment Barrett's adenocarcinoma by complete circular endoscopic submucosal dissection: a case report. <i>BMC Gastroenterology</i> , 2018, 18, 16.	0.8	6
81	Effect of furosemide on muscle cramps in patients with liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 76-81.	1.4	6
82	Zinc Administration and Improved Serum Markers of Hepatic Fibrosis in Patients with Autoimmune Hepatitis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2465.	1.0	6
83	DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis. <i>World Journal of Hepatology</i> , 2016, 8, 1194.	0.8	6
84	Association between Equol Production Status and Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11904.	1.8	6
85	Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats. <i>BMC Cancer</i> , 2018, 18, 1164.	1.1	5
86	Blocking development of liver fibrosis augments hepatic progenitor cell-derived liver regeneration in a mouse chronic liver injury model. <i>Hepatology Research</i> , 2019, 49, 1034-1045.	1.8	5
87	Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia. <i>Digestive Diseases</i> , 2020, 38, 329-334.	0.8	5
88	Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective single-center study. <i>Hepatology Research</i> , 2020, 50, 1101-1105.	1.8	5
89	The association of histological progression with biochemical response to ursodeoxycholic acid in primary biliary cholangitis. <i>Hepatology Research</i> , 2021, 51, 31-38.	1.8	5
90	Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 887-897.	0.8	5

#	ARTICLE	IF	CITATIONS
91	Angiotensin Receptor Blockers Potentiate the Protective Effect of Branched-Chain Amino Acids on Skeletal Muscle Atrophy in Cirrhotic Rats. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2100526.	1.5	5
92	Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis. <i>Indian Journal of Gastroenterology</i> , 2022, 41, 169-180.	0.7	5
93	Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan. <i>Anticancer Research</i> , 2022, 42, 173-183.	0.5	5
94	Rifaximin enhances the L-carnitine-mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut-liver-muscle axis. <i>International Journal of Molecular Medicine</i> , 2022, 50, .	1.8	5
95	A Patient with Hepatocellular Carcinoma with Isolated Right Atrial Metastases. <i>Internal Medicine</i> , 2017, 56, 2589-2594.	0.3	4
96	Effect of deferred or no treatment with ursodeoxycholic acid in patients with early primary biliary cholangitis. <i>Hepatology Research</i> , 2018, 48, 727-734.	1.8	4
97	Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 2743-2750.	0.8	4
98	Late-Evening Snack with Branched-Chain Amino Acid-Enriched Nutrients Does Not Always Inhibit Overt Diabetes in Patients with Cirrhosis: A Pilot Study. <i>Nutrients</i> , 2019, 11, 2140.	1.7	4
99	Clinical Significance of Gamma-Glutamyltranspeptidase Combined with Carbohydrate-Deficient Transferrin for the Assessment of Excessive Alcohol Consumption in Patients with Alcoholic Cirrhosis. <i>Medicines (Basel, Switzerland)</i> , 2021, 8, 39.	0.7	4
100	The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria. <i>Journal of Clinical Medicine</i> , 2021, 10, 4838.	1.0	4
101	Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 65-73.	4.5	4
102	Laser-cut-type versus braided-type covered self-expandable metallic stents for distal biliary obstruction caused by pancreatic carcinoma: a retrospective comparative cohort study. <i>Clinical Endoscopy</i> , 2022, 55, 434-442.	0.6	4
103	Clinical Significance of Serum Zinc Levels on the Development of Sarcopenia in Cirrhotic Patients. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 184-193.	0.3	4
104	Calcified mucinous adenocarcinoma of the stomach metastatic to the iris: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 64.	0.4	3
105	Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2'-deoxycytidine in Hepatic Stellate Cells. <i>Biology</i> , 2020, 9, 117.	1.3	2
106	Comparison of the efficacy and safety between palliative biliary stent placement and duct clearance among elderly patients with choledocholithiasis: a propensity score-matched analysis. <i>BMC Gastroenterology</i> , 2021, 21, 369.	0.8	2
107	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 1-1.	0.8	2
108	Comparison of Ablation Area and Change in Functional Liver Reserve after Radiofrequency Ablation for Hepatocellular Carcinoma Using the arfa® and VIVA® Systems. <i>Journal of Clinical Medicine</i> , 2022, 11, 434.	1.0	2

#	ARTICLE	IF	CITATIONS
109	Gastric granular cell tumor in a youth excised by endoscopic submucosal dissection : A case report and literature review. <i>Acta Gastro-Enterologica Belgica</i> , 2017, 80, 317-319.	0.4	2
110	Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 629.	1.0	1
111	Current status of hepatitis test recognition and an attempt of an efficient screening test in an area with a low implementation rate of hepatitis screening. <i>Acta Hepatologica Japonica</i> , 2021, 62, 89-91.	0.0	1
112	Therapeutic effect of dual oral therapy with daclatasvir and asunaprevir for choronic HCV patient with depression. <i>Acta Hepatologica Japonica</i> , 2016, 57, 496-498.	0.0	0
113	Spontaneously ruptured hepatocellular carcinoma in Fontan-associated liver disease: A case report. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X2092203.	0.2	0
114	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 30.	0.8	0
115	Endotoxin Activity Reflects an Increase in Body Temperature in Cirrhotic Patients With Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy. <i>In Vivo</i> , 2022, 36, 1477-1484.	0.6	0